Symbol not found

0.00 (0.00%)
Products, Strategic Combinations, Regulatory

Nicox's Licensee Bausch+Lomb Receives Approval For VYZULTA In UAE

Published: 06/25/2021 05:38 GMT
(BOL) - Reg-nicox’s Licensee Bausch + Lomb Receives Approval for Vyzulta® (latanoprostene Bunod Ophthalmic Solution), 0.024% in the United Arab Emirates.
Under Agreement, Nicox Receives Increasing Tiered Royalties of 6% to 12% on Net Global Sales of Vyzulta.
Under Agreement Receives Also Up to $150 Million in Potential Future Milestone Payments.